Arrivent Biopharma Inc (AVBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | 74,293 | 150,389 | 163,372 | 37,280 |
| Marketable Securities | 144,570 | N/A | N/A | N/A |
| TOTAL | $226,979 | $159,968 | $182,622 | $42,952 |
| Non-Current Assets | ||||
| Investments And Advances | 47,683 | 0 | 0 | 0 |
| Other Non-Current Assets | 280 | 3,130 | 211 | 87 |
| TOTAL | $47,963 | $3,130 | $211 | $87 |
| Total Assets | $274,942 | $163,098 | $182,833 | $43,039 |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 3,782 | 4,532 | 3,094 | 293 |
| Accrued Expenses | 13,330 | 6,952 | 5,138 | 1,525 |
| TOTAL | $17,274 | $11,624 | $8,360 | $1,818 |
| Non-Current Liabilities | ||||
| Other Non-Current Liabilities | 14 | 177 | 11 | 0 |
| TOTAL | $14 | $177 | $11 | $N/A |
| Total Liabilities | $17,288 | $11,801 | $8,371 | $1,818 |
| Shareholders' Equity | ||||
| Shares Outstanding, K | 34,016 | N/A | N/A | N/A |
| Common Shares | 3 | N/A | N/A | N/A |
| Retained earnings | -238,333 | -157,845 | -88,512 | -51,606 |
| Other shareholders' equity | -211 | 304,490 | 259,571 | 89,863 |
| TOTAL | $257,654 | $151,297 | $174,462 | $41,221 |
| Total Liabilities And Equity | $274,942 | $163,098 | $182,833 | $43,039 |